The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
4 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,537,882 in first-year total cost, median $395,702.
Most frequent study sections
- Special Emphasis Panel[ZCA1 TCRB-Q (J2)]4
Most frequent institutions
- APERTURE BIO, INC.1
- ARMA BIO, INC.1
- ATLAS BIOLOGICS, LLC1
- COSMYC INC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Development of small molecule therapeutics targeting AR-V7 for prostate cancer1R42CA290913-01 | AU, CHEUK MAN CHERIE | ARMA BIO, INC., NJ | $406,489 | ZCA1 |
| 2024 | Development of Deep Mutational Scanning with Duplex Sequencing (DMS-DS) for anti-cancer drug evaluation and administration1R42CA290940-01 | REYNOLDS, JOSHUA | ATLAS BIOLOGICS, LLC, PA | $400,000 | ZCA1 |
| 2024 | Therapeutic Inhibition of MYC:TRRAP Interaction in Cancer1R42CA290915-01 | FERIS, ED | COSMYC INC, DE | $391,403 | ZCA1 |
| 2024 | Rapid, Single Cell Proteomic Profiling for Biomarker Development in Precision Oncology1R42CA290912-01 | PETERSON, HANNAH MARIE | APERTURE BIO, INC., MA | $339,990 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.